Findings

What do systematic reviews say?

6 questions · 6 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 2 · 33.3%High 2 · 33.3%

DOAC vs variable dose warfarin

Major bleeding · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in major bleeding compared with warfarin (low certainty).

1 finding from 1 review

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation… 2017 · Cochrane Headline outcomes only
RR 0.79 [0.59, 1.04]
5 studies · 12521 participants
Low

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 1.65 [0.72, 3.8]
3 studies · 1440 participants
Moderate

DOAC vs placebo

Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
OR 1 [0.06, 16.02]
1 study · 2457 participants
Low

DOAC vs heparin

Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (high certainty).

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
OR 1.11 [0.79, 1.54]
5 studies · 16199 participants
High

DOAC vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding‐ clinically relevant non‐major Treatment duration 28 ‐ 42… compared with placebo (moderate certainty).

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
OR 1.22 [0.76, 1.95]
1 study · 2457 participants
Moderate

DOAC vs heparin

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ clinically relevant, non‐major Treatment duration 28 ‐ 42… compared with heparin (high certainty).

1 finding from 1 review

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or… 2016 · Cochrane Headline outcomes only
OR 1.08 [0.9, 1.28]
4 studies · 15241 participants
High